Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.

about

Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.

Item

http://www.wikidata.org/entity/Q54207293

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@en

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@nl

type

Item

label

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@en

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@nl

prefLabel

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@en

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@nl

P1476

Plectin-targeted liposomes enh ...... e treatment of ovarian cancer.

@en

P2093

Alexander L Klibanov

http://www.w3.org/2001/XMLSchema#string

Galina Diakova

http://www.w3.org/2001/XMLSchema#string

Jill K Slack-Davis

http://www.w3.org/2001/XMLSchema#string

Kimberly A Kelly

http://www.w3.org/2001/XMLSchema#string

Michael F Gutknecht

http://www.w3.org/2001/XMLSchema#string

Ryo Suzuki

http://www.w3.org/2001/XMLSchema#string

Siva Sai Krishna Dasa

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma

Plectin-1 as a novel biomarker for pancreatic cancer.

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Integrated genomic analyses of ovarian carcinoma

Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging

Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

Recent advances with liposomes as pharmaceutical carriers

Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction.

P304

2782-2798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/THNO.23050

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anne M Mills

P577

2018-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774075

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5957009

http://www.w3.org/2001/XMLSchema#string